Evidence map›Paper›PMID 40734949›Full record

ArticleNature and science of sleep2025

Gut Microbiome Composition Changes During Insomnia Treatment with Lemborexant.

Seiko Miyata, Kunihiro Iwamoto, Mikako Ito, Ippei Okada, Nao Matsuyama, Akihiro Fujimoto, Yuki Kogo, Hiroshi Nishiwaki, Jun Ueyama, Kinji Ohno and 1 more

Abstract read
In one paragraph

Article in Nature and science of sleep, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Seiko Miyata *Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.ORCID 0000-0002-1144-5676
Kunihiro Iwamoto *Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.ORCID 0000-0003-3868-3372
Mikako ItoDivision of Neurogenetics, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Ippei OkadaPharmaLex Japan, Inc., Shibuya, Tokyo, Japan.
Nao MatsuyamaDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Akihiro FujimotoMedical Headquarters, Eisai Co., Ltd., Bunkyo, Tokyo, Japan.
Yuki KogoMedical Headquarters, Eisai Co., Ltd., Bunkyo, Tokyo, Japan.
Hiroshi NishiwakiDivision of Neurogenetics, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Jun UeyamaDepartment of Biomolecular Sciences, Field of Omics Health Sciences, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Kinji OhnoDivision of Neurogenetics, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Norio OzakiDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Insomnia is a common disorder worldwide. Growing evidence has revealed that the microbiota-gut-brain axis contributes to the regulation of sleep continuity and duration, both directly and indirectly. Although lemborexant is effective in treating insomnia, its effect on the gut microbiota remains unclear. Here, we investigated the relationship between the gut microbiota and hypnotic use in insomnia. Participants and Methods: We enrolled 29 adults with insomnia and performed sleep electroencephalography and stool analyses at baseline and after 4 and 12 weeks of open-label lemborexant treatment. Changes in gut microbiota were analyzed using 16S rRNA sequencing and metabolite analysis was performed to assess short-chain fatty acids (SCFAs). Results: Beta diversity (Jaccard dissimilarity) and Firmicutes/Bacteroidetes ratio significantly increased after administration of lemborexant for 12 weeks (p < 0.05). Seven genera were significantly different (p < 0.05). Among these, Conclusion: Our findings suggest that prolonged lemborexant treatment in individuals with insomnia may induce notable shifts in gut microbiota composition, including a significant reduction in

Indexed as

elderlygut microbiotahome sleep monitoringinsomnia interventionlemborexantshort-chain fatty acids

Identifiers

PMID40734949
PMCPMC12306542

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.